Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

intrahepatic bile duct cancer - Clinical Profile, Genes & Research | Kisho | Kisho

Rare Disease

intrahepatic bile duct cancer

MONDO:0001487

Also known as:Ca intrahepatic bile ductscancer of intrahepatic bile ductmalignant intrahepatic bile duct neoplasm

Find Clinical TrialsTrials

Overview

A cancer that involves the intrahepatic bile duct.

TreatmentsNo approved treatments · 4 in pipeline

Clinical Trials5 registered · 2 recruiting

Diagnosis

Biomarker and diagnostic research for intrahepatic bile duct cancer has been reported in the published literature.

Treatment

Compiled from FDA-approved drug records, orphan drug designations, and FDA Adverse Event Reporting System (FAERS) safety data. GeneReviews management guidance is included where available.

No approved treatments are currently available for intrahepatic bile duct cancer. An additional 4 compounds hold orphan drug designation.

Orphan Drug Designations

While no drugs are FDA-approved specifically for intrahepatic bile duct cancer, some of the following designated compounds may be used off-label in clinical practice. Treatment decisions should be made in consultation with a specialist familiar with this condition.

The following drugs have received orphan drug designation from the FDA for intrahepatic bile duct cancer. Orphan designation reflects regulatory interest and does not indicate approval for treatment.

Brand Name	Generic Name	Sponsor

Research Landscape

Sourced from ClinicalTrials.gov and PubMed. Publication types are classified using NLM-curated article metadata; research type breakdowns reflect the nature of published work for this disease.

5 clinical trials registered, 2 recruiting. Interventions under study include drug therapy, other interventions, medical devices, and procedural interventions. Pipeline includes 2 PHASE2, 2 PHASE1, 1 NA. Research is primarily sponsored by academic and government institutions.

NCT ID	Title	Phase	Sponsor	Status
[NCT05286814](https://clinicaltrials.gov/study/NCT05286814)

Data assembled from 4 of 12 sources · Last updated Sep 20, 2026, 5:51 AM UTC

MONDOHPOClinicalTrials.govFDAPubMedHGNCClinVarClinGenGeneReviewsOrphanetOMIMRUSP

Medical References

Questions for Your Care Team

→Are any of the 5 active clinical trials a good fit for my situation?
→With 4 compounds in the orphan drug pipeline, which are furthest along in development and which clinical trials should I be aware of?
→Are there specialists or centers of excellence for this condition in my area?
→Is there a patient registry I should consider joining?

← Back to All Diseases

Research Type	Count	% of Total
Laboratory research	67	36%
Research summaries	48	26%
Disease patterns and progression	25	14%
Testing and diagnosis research	17	9%
New treatment approaches	12	6%
Clinical study results	8	4%
Patient case studies	6	3%
Other research	2	1%

intrahepatic bile duct cancer

Overview

Diagnosis

Treatment

Orphan Drug Designations

Research Landscape

Medical References

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

Clinical Trials

Recent Publications